ESMO-Magnitude of Clinical Benefit Scale

MCBS Banner 1180x184

The ESMO-MCBS is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies at the time of approval.

The below filter has been created to provide a centralised location of cancer medicines that have been scored using ESMO-MCBS v1.1 and published by ESMO.

ESMO-MCBS grading

Curative setting grading  - A (major benefit), B (important benefit), C (minor benefit):

  • Form 1   - For new approaches to adjuvant therapy or new potentially curative therapies

Non-curative setting grading - 5 and 4 (substantial benefit), 3 (moderate benefit), 2 and 1 (negligible benefit):

  • Form 2a   - For therapies that are not likely to be curative with primary endpoint of OS 
  • Form 2b   - For therapies that are not likely to be curative with primary endpoint PFS 
  • Form 2c   - For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies 
  • Form 3     - For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR 

For full information please click here

The ESMO-MCBS Score Card

The ESMO-MCBS Score Card allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Score card
T-DM1 Lapatinib + capecitabine 2nd line metastatic after trastuzumab failure (extensive crossover) Breast Cancer Breast Cancer HER2+ Metastatic
4
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo 1st line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Trastuzumab Lapatinib Lapatinib 3rd line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Palbociclib Fulvestrant Fulvestrant + placebo 2nd line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
4
Panitumumab FOLFOX4 FOLFOX4 1st line metastatic colorectal cancer (post hoc KRAS, NRAS BRAF WT) Gastrointestinal Cancers Colon and Rectal Cancer Metastatic
4
Cetuximab FOLFIRI FOLFIRI 1st line metastatic (post hoc KRAS, NRAS WT) Gastrointestinal Cancers Colon and Rectal Cancer RAS-WT Metastatic
4
Cetuximab Best supportive care Refractory metastatic KRAS-WT Gastrointestinal Cancers Colon and Rectal Cancer KRAS-WT Metastatic
4
Bevacizumab Chemotherapy Paclitaxel or topotecan or liposomal doxorubicin Recurrent platinum-resistant ovarian cancer Gynaecological Malignancies Ovarian Cancer Metastatic
4
Nivolumab Chemotherapy Platinum-refractory metastatic H+N squamous cell cancer Head and neck cancer Squamous cell Metastatic
4
Erlotinib Carboplatin gemcitabine 1st line stage III or IV non-squamous, with EGFR mutation Thoracic Malignancies Non-small-cell Lung Cancer EGFR+ Metastatic
4

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings